Patents Examined by Michael C. Wilson
  • Patent number: 10655103
    Abstract: An isolated mammalian progenitor cell or its progeny, isolated from articular cartilage, is disclosed. Further is disclosed an equine progenitor cell isolated from the surface zone of equine articular cartilage tissue and uses thereof. Also disclosed are a method of tissue repair, a medicament, and a method of treating mammalian cartilage damage using such progenitor cells or progeny.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: May 19, 2020
    Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED
    Inventors: Charles William Archer, Helen Elizabeth McCarthy
  • Patent number: 10653782
    Abstract: Compositions and methods are provided for improved wound healing. In particular, provided herein are compositions and methods for the direct delivery of Sirtuin-1 (Sirt1) or vectors encoding Sirt1 to the wounds (e.g., of diabetic patients). In some embodiments, provided herein are therapeutic devices comprising: (a) a vector encoding Sirtuin-1 (Sirt 1); and (b) a hydrogel carrier. In some embodiments, the vector comprises a viral vector comprising a polynucleotide sequence encoding Sirt 1. In some embodiments, the vector comprises a non-viral vector comprising a polynucleotide sequence encoding Sirt1.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: May 19, 2020
    Assignee: Nortwestern University
    Inventors: Guillermo A. Ameer, Michele Jen
  • Patent number: 10648001
    Abstract: Nucleases and methods of using these nucleases for inserting a sequence encoding a therapeutic protein such as an enzyme into a cell, thereby providing proteins or cell therapeutics for treatment and/or prevention of a lysosomal storage disease.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 12, 2020
    Assignee: Sangamo Therapeutics, Inc.
    Inventor: Edward J. Rebar
  • Patent number: 10639355
    Abstract: The invention provides a novel anticancer therapeutic having a high effect against solid cancers, lacking the side effects of chemotherapeutics, and being unlikely to cause resistance. Provided is a pharmaceutical composition for cancer treatment prepared by a method having: a stem cell production step for making immortalized stem cells by introducing four types of genes into deciduous tooth dental pulp stem cells obtained from the dental pulp of mammals; and a condition medium preparation step for culturing the immortalized stem cells for a predetermined length of time in serum-free medium at 23-27° C. under conditions of low oxygen concentration at an oxygen concentration of from 0.5% to less than 20%, the pharmaceutical composition containing 1.5 times or more of insulin-like growth factor (IGF-1) and vascular endothelial growth factor (VEGF) than is contained in condition medium prepared when culturing at an oxygen concentration of 20% and otherwise identical conditions.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 5, 2020
    Assignee: QUARRYMEN & Co. Inc.
    Inventor: Minoru Ueda
  • Patent number: 10604771
    Abstract: Disclosed herein are methods and compositions for delivery of engineered nucleases and donor molecules into the genome of a cell.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: March 31, 2020
    Assignees: Sangamo Therapeutics, Inc., University of Southern California
    Inventors: Paula M. Cannon, Colin Michael Exline, Michael C. Holmes
  • Patent number: 10575505
    Abstract: An object of the present invention is to provide a mouse that enables the functions of human NK cell to be studied. A DNA consisting of a nucleotide sequence represented by SEQ ID NO: 1, which is a gene region comprising a DNA in which a cDNA sequence encoding interleukin 15 (IL-15) is operably ligated to a cDNA sequence encoding the signal peptide of human interleukin (IL-2), is inserted to immunodeficient mouse cDNA. In NOD-scid, IL-2r?null-hIL-15 Tg mice thus generated, hCD56+ cell having a concentration sufficient for conducting in vivo study on human mature NK cell are detected for at least 6 months after transplantation.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: March 3, 2020
    Assignee: Central Institute for Experimental Animals
    Inventors: Mamoru Ito, Ikumi Katano
  • Patent number: 10544394
    Abstract: The present invention relates to methods of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC) and/or progeny derived therefrom in vitro or in vivo comprising exposing the MPC or progeny to SDF-1 or analog thereof. The invention also relates to compositions comprising isolated MPCs or progeny derived therefrom and SDF-1 or analogues thereof. The present invention also relates to using such methods and compositions for ex vivo or in vivo bone formation in mammals.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: January 28, 2020
    Assignee: Mesoblast, Inc.
    Inventors: Stan Gronthos, Andrew Christopher William Zannettino
  • Patent number: 10531648
    Abstract: A genetically modified mouse is provided that comprises a conditional Acvr1 allele that comprises a mutated exon that, upon induction, converts to a mutant exon phenotype, wherein the mutant exon phenotype includes ectopic bone formation. Mice comprising a mutant Acvr1 exon 5 in antisense orientation, flanked by site-specific recombinase recognition sites, are provided, wherein the mice further comprise a site-specific recombinase that recognizes the site-specific recombinase recognitions sites, wherein the recombinase is induced upon exposure of the mouse to tamoxifen. Upon exposure to tamoxifen, the recombinase is expressed and acts on the RRS-flanked mutant exon 5 and places the mutant exon 5 in sense orientation and deletes the wild-type exon.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: January 14, 2020
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Aris N. Economides, Sarah Jane Hatsell
  • Patent number: 10501726
    Abstract: The present invention relates to the production of avian induced pluripotent stem cells from non-pluripotent somatic cells, including embryonic fibroblasts and adult somatic cells. In this method, avian (including quail or chicken) somatic cells are reprogrammed into a state closely resembling embryonic stem cells including the expression of key stem cell markers alkaline phosphatase, etc. by transfecting/transducing the non-stem cells with genes (preferably using a non-integrating vector as otherwise described herein or alternatively an integrating vector, such a lentiviral vector, retroviral vector or inducible lentiviral vector, among others) which express at least nanog, Lin28 and cMyc. In preferred aspects of the invention, the transfected/transduced vectors express nanog, Lig28, cMyc, Oct 4 (POU5F1 or PouV), SOX2 and KLF4. The induced stem cells which are produced contribute to all 3 germ layers, the trophectoderm and in certain aspects, the gonad in chimeric offspring.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 10, 2019
    Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: Steven L Stice, Franklin West, Yangqing Lu
  • Patent number: 10470444
    Abstract: A genetically modified mouse is provided that comprises a conditional Acvr1 allele that comprises a mutated exon that, upon induction, converts to a mutant exon phenotype, wherein the mutant exon phenotype includes ectopic bone formation. Mice comprising a mutant Acvr1 exon 5 in antisense orientation, flanked by site-specific recombinase recognition sites, are provided, wherein the mice further comprise a site-specific recombinase that recognizes the site-specific recombinase recognitions sites, wherein the recombinase is induced upon exposure of the mouse to tamoxifen. Upon exposure to tamoxifen, the recombinase is expressed and acts on the RRS-flanked mutant exon 5 and places the mutant exon 5 in sense orientation and deletes the wild-type exon.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: November 12, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Aris N. Economides, Sarah Jane Hatsell
  • Patent number: 10463718
    Abstract: The invention provides improved adeno-associated virus (AAV) Factor VIII (FVIII) vectors, including AAV FVIII vectors that produce a functional Factor VIII polypeptide and AAV FVIII vectors with high expression activity.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: November 5, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Peter Cameron Colosi, Amit Nathwani, Jenny McIntosh, Edward Tuddenham
  • Patent number: 10448621
    Abstract: A genetically modified mouse is provided that comprises a conditional Acvr1 allele that comprises a mutated exon that, upon induction, converts to a mutant exon phenotype, wherein the mutant exon phenotype includes ectopic bone formation. Mice comprising a mutant Acvr1 exon 5 in antisense orientation, flanked by site-specific recombinase recognition sites, are provided, wherein the mice further comprise a site-specific recombinase that recognizes the site-specific recombinase recognitions sites, wherein the recombinase is induced upon exposure of the mouse to tamoxifen. Upon exposure to tamoxifen, the recombinase is expressed and acts on the RRS-flanked mutant exon 5 and places the mutant exon 5 in sense orientation and deletes the wild-type exon.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: October 22, 2019
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Aris N. Economides, Sarah Jane Hatsell
  • Patent number: 10435677
    Abstract: The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic stem cell.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 8, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Gregory J. Cost, Jeffrey C. Miller, Lei Zhang
  • Patent number: 10426848
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: October 1, 2019
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
  • Patent number: 10392600
    Abstract: The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. In accordance with the present invention, a selectable marker gene has been recombinantly targeted to the brachyury locus to allow the isolation and characterization of cell populations that comprise brachyury positive mesendoderm and mesoderm cells. The cell populations of the invention are useful for generating cells for cell replacement therapy.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: August 27, 2019
    Assignee: ICAHN School of Medicine at Mount Sinai
    Inventors: Gordon Keller, Valerie Kouskoff, Atsushi Kubo, Hans J. Fehling
  • Patent number: 10385318
    Abstract: Disclosed herein are methods of producing induced pluripotent stem cells from chondrocytes, and further, methods of producing chondrocytes from said induced pluripotent stem cells. The invention further provides methods of regenerating cartilaginous tissue.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: August 20, 2019
    Assignee: SCRIPPS HEALTH
    Inventors: Darryl D. D'Lima, Tsaiwei Olee, Clifford W. Colwell
  • Patent number: 10377991
    Abstract: This invention provides a method for stably producing airway epithelial cells from pluripotent stem cells. Specifically, the invention relates to a method for producing airway epithelial cells from pluripotent stem cells comprising steps: (1) culturing pluripotent stem cells in a medium containing activin A and a GSK3? inhibitor; (2) culturing the cells obtained in Step (1) in a medium containing a BMP inhibitor and a TGF? inhibitor; (3) culturing the cells obtained in Step (2) in a medium containing BMP4, retinoic acid, and a GSK3? inhibitor; (5) subjecting the cells obtained after Step (3) to three-dimensional culture in a medium containing a GSK3? inhibitor, FGF10, and a ROCK inhibitor; and (6) subjecting the proximal airway epithelial progenitor cells obtained in Step (5) to three-dimensional culture in a medium containing a ROCK inhibitor.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: August 13, 2019
    Assignee: KYOTO UNIVERSITY
    Inventors: Shimpei Gotoh, Yuki Yamamoto, Satoshi Konishi, Michiaki Mishima
  • Patent number: 10370680
    Abstract: Disclosed herein are methods and compositions for targeted, nuclease-mediated insertion of transgene sequences into the genome of a cell.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: August 6, 2019
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Michael C. Holmes, Thomas Wechsler
  • Patent number: 10350275
    Abstract: A method is disclosed for decreasing or retarding an increase in the size of a localized or metastatic tumor by using a combination of an immune stimulating cytotoxic gene therapy and immune-checkpoint modulating agent, in conjunction with other therapies, including radiation therapy, chemotherapy, surgery, and immunotherapies.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: July 16, 2019
    Assignee: Advantagene, Inc.
    Inventor: Carlos Estuardo Aguilar-Cordova
  • Patent number: 10344265
    Abstract: Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: July 9, 2019
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Derrick Rossi, Luigi Warren